Discngine’s Post

A masterpiece in enzymology, what a pleasure to see this in the publication landscape!

Ensuring successful #oligonucleotidetherapeutics development demands specialized bioanalytical and CMC support.  Experts are rare in this field. Finding labs with expertise in oligonucleotide analysis is a challenge and smaller #CROs often lack the necessary equipment.  Don’t give up control. Choose Sannova:  #boutiqueCRO services for personalized, transparent preclinical support.  Expert Advice for #ASOs, siRNA and miRNA analysis, pharmacokintetic (PK), toxicokinetic (TK) studies. Quick turnarounds for fast progress and regulatory review. For a free demonstration of our capabilities in action download our brand new whitepaper, offering exclusive insights into siRNA quantification. #bioanalyticalexcellence

Exploring the structure-activity relationship (SAR) of a small molecule has led to the creation of SJ3149. This degrader of CK1α protein has shown to be effective and selective in both in vitro and in vivo settings. The co-crystal structure of SJ3149 with CK1α + CRBN + DDB1 has shed light on its enhanced degradation properties. Check out the full article for more information on this exciting breakthrough! #drugdiscovery #drugdevelopment #degrader #molecularglue https://lnkd.in/eEg-uf8h

#BrightGene's dual GLP-1/GIP receptor agonist, BGM0504, demonstrates superior efficacy in both in vitro and in vivo experiments due to optimal interaction between the glutamate residues on both GLP-1R and GIPR and the K20 residue of a peptide agonist. https://lnkd.in/d-5W2x4E #TechNews #StayInformed #StayAhead #dailydose #followus #staytuned #stayconnected #technews #technology #trending #trendingnow #trendingnews #explore #explorepage #techdogs

Let’s connect on X All the latest trends and updates in oligonucleotide therapeutics and Diagnostics https://lnkd.in/d_5jXE9V 1. **Gene Editing Advancements:** Continued progress in CRISPR-based technologies for precise gene editing using oligonucleotides, offering potential treatments for genetic disorders. 2. **RNA Therapeutics:** Growing focus on RNA-based therapies, including messenger RNA (mRNA) vaccines and RNA interference (RNAi) for targeted gene silencing. 3. **Antisense Oligonucleotides (ASOs):** Ongoing development and clinical trials of ASOs, designed to modulate gene expression by binding to specific RNA sequences, for various diseases including neurodegenerative disorders. 4. **Delivery Systems:** Advancements in delivery methods to enhance the efficient and targeted delivery of oligonucleotides, addressing challenges related to stability, uptake, and distribution within the body. 5. **Diagnostic Applications:** Increasing use of oligonucleotides in molecular diagnostics, such as detecting specific genetic mutations, monitoring disease progression, and personalized medicine approaches. 6. **Therapeutic Pipeline Expansion:** Continued growth in the number of oligonucleotide-based therapies in clinical trials, spanning various therapeutic areas including oncology, rare diseases, and infectious diseases. 7. **Next-Generation Sequencing (NGS):** NGS technologies utilizing oligonucleotides play a crucial role in genomic research and diagnostics, enabling comprehensive genetic analysis with increased speed and accuracy. Keep in mind that the field evolves rapidly, and it's essential to check the latest literature and industry updates for the most current trends and developments in oligonucleotide therapeutics and diagnostics.

A new #preprint describing a thermostable RNase inhibitor: "Over the past decade, there have been remarkable technical improvements in most aspects of single-cell transcriptomics. Yet, there has been little to no progress in advancing RNase inhibition despite that maintained RNA integrity is critical during cell collection, storage, and cDNA library generation. Here, we demonstrate that a synthetic thermostable RNase inhibitor yields single-cell libraries of equal or superior quality compared to ubiquitously used protein-based recombinant RNase inhibitors" https://lnkd.in/dFq8hUva

Learn about the industry's requirements for expanding LNPs into gene editing, oncology, and protein replacement. Scott Ripley discusses the evolving manufacturing landscape and the development of the NanoAssemblr commercial formulation system. #LNPs #BiotechInnovation https://lnkd.in/drdfwC6G

🔬 𝐎𝐩𝐭𝐢𝐦𝐢𝐳𝐞 𝐘𝐨𝐮𝐫 𝐂𝐞𝐥𝐥 𝐁𝐢𝐨𝐥𝐨𝐠𝐲 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐰𝐢𝐭𝐡 𝐀𝐜𝐜𝐮𝐫𝐚𝐭𝐞 𝐂𝐞𝐥𝐥 𝐏𝐫𝐨𝐥𝐢𝐟𝐞𝐫𝐚𝐭𝐢𝐨𝐧 & 𝐂𝐲𝐭𝐨𝐭𝐨𝐱𝐢𝐜𝐢𝐭𝐲 & 𝐕𝐢𝐚𝐛𝐢𝐥𝐢𝐭𝐲 𝐃𝐞𝐭𝐞𝐜𝐭𝐢𝐨𝐧! Cell proliferation and cytotoxicity assays are essential tools for evaluating cell activity, genotoxicity, and the effects of antitumor drugs. Whether you're assessing cell growth, viability, or mitochondrial function, the right detection kit can make all the difference. At Elabscience, we offer a range of reliable kits, including EdU, Calcein AM/PI, CCK-8, and LDH, to meet your specific experimental needs. Whether you are monitoring cell viability or investigating DNA damage, our solutions are designed to deliver accurate and reproducible results. Discover the ideal kit for your research and ensure precision in every experiment! 🔗 https://lnkd.in/gyAzPD5R #CellBiology #Cytotoxicity #CellProliferation #Elabscience #EdU #CCK8 #CellGrowth #DNA

Learn about the industry's requirements for expanding LNPs into gene editing, oncology, and protein replacement. Scott Ripley discusses the evolving manufacturing landscape and the development of the NanoAssemblr commercial formulation system. #LNPs #BiotechInnovation https://lnkd.in/emWByEPD

PMOs, short for phosphorodiamidate morpholino oligomers, are short single-stranded DNA analogs that are built upon a backbone of morpholine rings connected by phosphorodiamidate linkages. They bind to complementary sequences of target mRNA to block protein translation through steric blockade. Their interference of viral protein translation operates independently of RNAse H and are resistant to a variety of enzymes present in biologic fluids, making them highly suitable for in vivo applications. PMO-based therapy for Duchenne muscular dystrophy (DMD) has become a hallmark for PMO-based antisense therapy. Here's a link to a nice write-up on the history on PMO's: https://lnkd.in/gvzUr6jv. as well as the challenges and strategies of Antisense Oligonucleotide Drug Delivery: https://lnkd.in/gQd2V5Bk